Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3157663 A
Publication typeGrant
Publication dateNov 17, 1964
Filing dateNov 20, 1962
Priority dateNov 20, 1962
Publication numberUS 3157663 A, US 3157663A, US-A-3157663, US3157663 A, US3157663A
InventorsBencze William Laszlo
Original AssigneeCiba Geigy Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
3-(amino-phenyl)-2-(pyridyl)-acrylonitriles
US 3157663 A
Images(3)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent 3,157,663 3-(AMlN0-PHENYL)-2-(PYRIDYL)- ACRYLONITRILES William Laszlo Bencze, New Providence, N.J., assignor to Ciba Corporation, New York, N.Y., a corporation of in which Py is pyridyl, and Am stands for an amino group, or salts thereof, as well as process for the preparation of these compounds.

The pyridyl radical Py represents 3-pyridyl or 4-pyridyl, as well as 2-pyridyl, or substituted pyridyl, such as (lower alkyl)-pyridyl, in which lower alkyl has from one to seven, preferably from one to four, carbon atoms, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl and the like, (lower alkoxy)-pyridyl, in which lower alkoxy has from one to seven, preferably from one to four carbon atoms, e.g. methoxy, ethoxy, isopropyloxy, n-butyloxy and the like, (halogeno)-pyridyl, in which halogeno has preferably an atomic weight between 19 and 80, e.g. fluoro, chloro or bromo.

The amino group Am may stand for unsubstituted amino, N-lower alkyl-amino, e.g. N-methyl-amino, N- ethyl-amino, N-propyl-amino and the like, or N,N-dilower alkylamino, e.g. N,N-dimethyl-amino, N-ethyl-N- methyl-amino, N,N-diethyl-amino and the like. The amino group Am may substitute any of the positions of the phenyl nucleus, but is attached preferably to the 4- position (p-position).

Salts of the compounds of this invention are acid addition salts, such as pharmaceutically acceptable, non-toxic acid addition salts with inorganic acids, e.g. hydrochloric, hydrobromic, nitric, sulfuric, phosphoric acids and the like, or with organic acids, such as organic carboxylic acids, e.g. acetic, propionic, glycolic, malonic, succinic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric, benzoic, salicyclic, 4-aminosalicylic, 2-phenoxybenzoic, 2- acetoxybenzoic acid and the like, or with organic sulfonic acids, e.g. methane sulfonic, ethane sulfonic, Z-hydroxyethane sulfonic, ethane 1,2-disulfonic, toluene sulfonic acid and the like. Other acid addition salts may be used as intermediates, for example, in the purification of the free compounds or preparation of other acid addition salts, as well as for identification or characterization purposes. Salts for identification purposes are, for example, those with acidic organic nitro compounds, e.g. picric, fiavianic, picrolonic acid and the like, or with complex metal acids, e.g. phosphotungstic, phosphomolybdic, chloroplatinic, Reinecke acid and the like.

The compounds of the present invention may be in the form of mixture of isomers (i.e. racem-ates and the like) or of single isomers.

The compounds of this invention inhibit certain functions of the adrenal cortex. Thus, they cause a decrease of the secretion of hydrocortisone (Compound F) and an increase of the excretion of corticosterone (Compound B), while the secretion of 11-desoxy-l7a-hydroxycorticosterone (Compound S) remains unchanged; it appears that they inhibit the 17a-hydroxylase enzyme system. The compounds of the present invention, possessing the above 3,157,663 Patented Nov. 17, 1964 2 described specific adrenal cortical inhibitory activity, can be used as diagonostic tools for the determination of the functioning of the pituitary gland, or as agents in the treatmerit of conditions due to adrenal cortical hyperf'unction, e.g. Cushings syndrome, primary aldosteronism, secondary aldosteronism and the like. Futhermore, the preferential inhibition of the 17u-hydroxylase enzyme system makes the compounds of this invention useful as aids in the study of the biosynthetic pathways of c'orticoid hormone formation.

The compounds of this invention may be used in the form of composition suitable for enteral or parenteral administration, which contain the pharmacologically active compounds in admixture with a pharmaceutical organic or inorganic, solid or liquid carrier. For making up the preparations there can be employed substances which do not react with the new compounds, such as water, gelatine, lactose, starches, stearic acid, magnesium stearate, talc, vegetable oils, benzyl alcohols, stearyl alcohol, tragacanth, gums, propylene glycol, polyalkylene glycols or any other known carrier used for pharmaceutical preparations. The latter may be in solid form, for example, as capsules, tablets, dragees and the like, or in liquid form, for example, as solutions, suspensions, emulsions and the like. If desired, they may contain auxiliary substances, such as preserving, stabilizing, wetting, emulsifying, coloring, flavoring agents and the like, salts for varying the osmotic pressure, buffers, etc. They may also contain, in combination, other useful substances.

The 3-(amino-phenyl)-2-(pyridyl)-acrylonitrile compounds of this invention, having the formula in which Py and Am have the previously-given meaning, or the salts thereof, may be prepared, for example, by treating a pyridyl-acetonitrile of the formula in which Py has the previously-given meaning, with an amino-benzaldehyde, of the formula Am-C H CHO, in which Am has the previously-given meaning, and, if desired, converting a resulting salt into the free compound or into another salt, and/or, if desired, converting a resulting compound into a salt thereof, and/or, if desired, separating a mixture of isomers into the single isomers.

The above reaction is carried out according to known methods; preferably, it is performed in the presence of a base, such as, for example, an alkali metal lower alkanolate, e.g. lithium, sodium or potassium methanolate, ethanolate, n-butanolate, tertiary butanolate and the like, a strong quaternary ammonium hydroxide, e.g. benzyl trimethyl ammonium hydroxide and the like, or any other equivalent basic reagent, e.g. piperidine and the like, and of a suitable inert solvent, e.g. methanol, ethanol and the like, if necessary, while cooling or at an elevated temperature, in a closed vessel, and/or in the atmosphere of an inert gas, e.g. nitrogen and the like.

Compounds of this invention may also be prepared by converting in a compound having the formula in which Py has the previously given meaning, or a salt thereof, the nitro group into the desired amino group Am by reduction, and, if desired, carrying out the optional steps.

Conversion of the nitro group into amino carried out according to known methods, for example, by treating the starting material with a reducing reagent, such as a metal (iron, tin and the like) in the presence of an acid (hydrochloric, sulfuric acid and the like), catalytically activated hydrogen (hydrogen in the presence of Raney nickel, platinum oxide and the like, under controlled conditions), or any other suitable reducing reagent. A nitro' group may be converted into an N-lower alkylamino or an N,N-di-lower alkyl-amino group by reductive alkylation, for example by carrying out the reduction, particularly with catalytically activated hydrogen, in the presence of an aldehyde (e.g. formaldehyde and the like) or a ketone. Methods for the reduction of a nitro group into an amino group Am are referred to by Wagner and Zook, Synthetic Organic Chemistry, p. 653 (Wiley, 1953).

The starting material used in the above precedure is prepared according to known methods, such as, for example, one of the previously mentioned procedures.

A salt resulting from one of the above procedures may be converted into the free base according to known methods, for example, by treatment with an alkaline reagent, such as an alkali metal hydroxide, e.g. lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, an alkali metal carbonate, e.g. sodium or potassium carbonate or hydrogen carbonate and the like, ammonia, or any other suitable reagent, such as a hydroxyl ion exchange preparation and the like.

A resulting salt may be converted into another salt, for example, by reacting the former with an inorganic salt of an inorganic or organic acid, such as a silver, sodium and the like, salt of such acid, or with a suitable anion exchange preparation.

A free base may be converted into a salt according to known methods, for example, by treating a solution of the base in an inert solvent or solvent mixture with the appropriate acid, such as one of the above-mentioned inorganic or organic acids, if desired, a solution thereof in an inert solvent or solvent mixture, and isolating the desired salt. Salts may be isolated in the form of hydrates.

Resulting mixtures of isomers may be converted into the single isomers according to known methods. For example, racemates may be resolved into the optically active dand l-forms, for example, by treating a racemic mixture, preferably in solution with an inert solvent or solvent mixture, with one of the optically active forms of an acid containing an asymmetric carbon atom, or a solution thereof, and isolating the resulting salt. Especially useful as optically active forms of salt-forming acids having an asymmetric carbon atom are D-tartaric (l-tartaric) acid of L-tartaric (d-tartaric) acid; the optically active forms of rhalic, mandelic, camphor-lO-sulfonic, quinic acid and the like, may also be used. A resulting salt may be converted into the free and optically active base according to process as outlined hereinbefore, and an optically active base may be converted into an acid addition salt or a quaternary ammonium compound, according to the previously-mentioned methods. Mixtures of other isomers, e.g. diastereoisomers, are separated on the basis of physicochemical differences, e.g. solubility and the like.

The invention also comprises any modification of the process wherein a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining step(s) of the process is(are) carried out, as well as any new intermediates.

This is a continuation-in-part application of my application Serial No. 165,324, filed January 110, 1962, now abandoned.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees centigrade.

Example 1 To a solution of 6.0 g. of 4-N,N-dimethylaminobenzaldehyde and 6.0 g. of (3-pyridyl)-acetonitrile in 20 ml. of methanol is added approximately 0.1 g. of sodium methanolate while stirring. Within five minutes, the reaction mixture solidifies and is diluted with Water. The solid material is filtered off and washed with water to yield the desired 3-(4-N,N-dimethylaminophenyl)-2-(3-pyridyl) -acrylonitrile of the formula which is recrystallized from aqueous ethanol and a mixture of ethyl acetate and pentane, M.P. 142-143.

Other 3 (amino-phenyl)-2-(pyridyl)-acrylonitriles, such as 3-(4-arnino-phenyl)-2-(3-pyridyl)-acrylonitrile, 3-(4-N-methyl-amino=phenyl)-2-(2 pyridyl) acrylonitrile, 3 (3 -N,N-dimethylamino-phenyl)-2-(4-pyridyl)- acrylonitrile and the like, may be prepared according to the above procedure.

Example 2 To a solution of 3.0 g. of (4-pyridyl)-acetonitrile in 15 ml. of percent ethanol is added a solution of 3.7 g. of 4-N,N-diyethylamino-benzaldehyde in 10 ml. of 95 percent ethanol while stirring. Small portions of solid sodium methanolate are added until a precipitate is formed, and the mixture solidifies. Water is added, the yellow solid is filtered off and is recrystallized from a mixture of ethanol and water to yield 2.8 g. of 3-(4-N,N-dimethylamino)-2-(4-pyridyl)-acrylonitrile of the formula which melts at l81l82.

Example 3 To a solution of 2.5 g. of 3-(4-nitro-phenyl)-2-(4-pyridyl)-acrylonitrile in ml. of p-dioxane is added 1.0 g. of a palladium catalyst (5 percent palladium on charcoal), and the mixture is treated with hydrogen at atmospheric pressure. After the uptake of the theoretical amount of hydrogen, the hydrogenation is interrupted, the catalyst is filtered off and the filtrate is evaporated to dryness. The yellow solid is recrystallized from ethanol to yield the desired 3-(4-amino-phenyl)-2-(4-pyridyl)- acrylonitrile of the formula which melts at 224-227".

The starting material used in the above reaction is prepared as follows: To a solution of 3.0 g. of (4-pyridyl)-acetonitrile and 3.8 g. of 4-nitro-benzaldehyde in 95 ethanol are added while stirring small portions of solid sodium methanolate until the solution begins to darken. During the exothermic reaction a solid material precipitates, the reaction mixture is diluted with Water, and the solid material is filtered olf. The desired 3-(4-nitrophenyl) -2-(4-pyridyl) acrylonitrile melts at 199-200 after recrystallization from ethanol.

What is claimed is:

1. A member selected from the group consisting of a compound of the formula in which Py is pyridyl, and Am is a member selected from the group consisting of amino, N-lower alkyl-arnino and N,N-di-lower alkyl-amino, and a pharmaceutically acceptable, non-toxic acid addition salt thereof.

2. 3-(4-N,N-dimethy1a.mino-phenyl) 2 (3-pyridy1)- References Cited in tha file of this patent acrylonitrile.

3. 3- 4 N,N dimethylamino-phenyl)-2-(4-pyridy1)- UNITED STATES PATENTS acrylonitflle, 2,567,245 Sperber et a1. Sept. 11, 1951 4. 3-(4-amino-phenyl)-2-(4-pyridyl)-acry1onitrile. 5 2,727,895 Sperber et a1. Dec. 20, 1955

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US2567245 *May 10, 1948Sep 11, 1951Schering CorpAryl-(2-pyridyl)-amino alkanes and their production
US2727895 *May 11, 1953Dec 20, 1955Schering CorpAlpha-alkylated, 4-benzyl pyridines and certain substitution derivatives
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4102644 *Sep 3, 1976Jul 25, 1978Milliken Research CorporationPolymeric dyestuff containing di(polyoxyethylene) amino group
US4312985 *Aug 29, 1980Jan 26, 1982Eastman Kodak CompanyDisperse dyes from heterocyclic acetonitriles
US4316013 *Aug 29, 1980Feb 16, 1982Eastman Kodak CompanySubstituted heterocyclic methine dyes
US4600712 *Oct 9, 1985Jul 15, 1986Shell Oil CompanyFungicidally active compositions containing ethene derivatives
US4640690 *Sep 13, 1985Feb 3, 1987Milliken Research CorporationColored thermoplastic resin composition containing a colorant having an alkylenoxy-substituted chromophore group
US5196446 *Apr 16, 1991Mar 23, 1993Yissum Research Development Company Of The Hebrew University Of JerusalemTreatment of psoriasis, atherosclerosis
US5302606 *Apr 16, 1991Apr 12, 1994Rhone-Poulenc Rorer Pharmaceuticals Inc.Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5418245 *Mar 17, 1994May 23, 1995Rhone-Poulenc Rorer International (Holdings) Inc.For inhibiting cell proliferation
US5597837 *Apr 11, 1994Jan 28, 1997Rh one-Poulenc Rorer Pharmaceuticals Inc.Method and composition for treating psoriasis with styryl-substituted pyridyl compounds
US5656655 *May 19, 1995Aug 12, 1997Rhone-Poulenc Rorer Pharmaceuticals, Inc.Administering; useful for treating cell proliferation disorder such as psoriasis
US5677329 *May 19, 1995Oct 14, 1997Rhone-Poulenc Rorer Pharmaceuticals, Inc.Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US6083310 *May 28, 1998Jul 4, 2000Marconi Data Systems, Inc.Colored inks comprising polymeric colorants for binary array printing and method of using
US7399566Jan 18, 2005Jul 15, 2008Milliken & CompanyThermoplastic resin; charge control agent; and polyoxyalkylene- or polylactone-substituted color chromophores which are attached to relatively long chained oligomers; for use in electrophotographic imaging devices
US7662461Mar 31, 2006Feb 16, 2010Milliken & CompanySynthetic leather articles and methods for producing the same
US7824737Jun 17, 2009Nov 2, 2010Milliken & CompanySynthetic leather articles and methods for producing the same
US7872069Mar 21, 2007Jan 18, 2011Milliken & Companysubstrate of textile materials, leathers, thermoplastic resins, thermoset resins coated with a polyurethane and an active hydrogen-terminated colorant,
US8431648Jan 17, 2011Apr 30, 2013Milliken & CompanyCoated substrates and polymer dispersions suitable for use in making the same
DE112007002683T5Nov 1, 2007Mar 18, 2010Milliken & Co.Farbmittelzusammensetzungen und ihre Verwendung als pH-empfindliche Farbindikatoren
EP0104690A2 *Aug 30, 1983Apr 4, 1984Shell Internationale Research Maatschappij B.V.Fungicidally active compositions containing ethene derivatives
WO1991016051A1 *Apr 16, 1991Oct 31, 1991Rorer Int HoldingsStyryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
WO2006004876A1Jun 29, 2005Jan 12, 2006Procter & GambleLaundry detergent compositions with efficient hueing dye
Classifications
U.S. Classification546/330, 424/9.1
International ClassificationC07D213/57
Cooperative ClassificationC07D213/57
European ClassificationC07D213/57